Bisphosphonates do not impair fracture healing rate or timeline in osteoporotic patients, while teriparatide may accelerate union without delaying recovery. This systematic review clarifies medication safety during the critical window when skeletal integrity is compromised, directly informing treatment decisions for aging populations at high fracture risk.
Key Points
- Bisphosphonates do not slow fracture healing or union rates
- Teriparatide may accelerate healing in osteoporotic fractures
- Heterogeneous reporting limits comparative efficacy assessment across agents
Longevity Analysis
For individuals with compromised bone density, the choice between anti-osteoporotic medications has been complicated by concerns that treatment might interfere with the body's natural repair capacity after fracture. This analysis removes a significant barrier: bisphosphonates preserve the healing process while maintaining their fracture prevention benefit. Teriparatide's potential to accelerate union adds a secondary advantage during the vulnerable post-fracture period. The clinical implication is straightforward—medication selection can now prioritize efficacy and patient tolerance without sacrificing bone's regenerative capacity. However, the variability in study protocols and reporting standards means clinical decisions should remain individualized until standardized evidence emerges.
Original published by The Lancet Healthy Longevity, by Nikhil Agarwal, Katrina R Bell, Lauren E Ross, Nick D Clement, Stuart H Ralston, Andrew D Duckworth.